Entry Rationale
Entry was considered under the judgment that, as the current stock price exceeds the previous 20-day resistance line, approaching the stock after confirming the short-term support line is valid.
Moderna rallies 12% to set new high
Moderna surged 12% to reach a new high.
Entry was considered under the judgment that, as the current stock price exceeds the previous 20-day resistance line, approaching the stock after confirming the short-term support line is valid.
Since the current stock price is above the resistance level, it is advisable to approach the stock after confirming the short-term support level. Take profit at 161.96 and cut losses at 130.0 — cut losses if the conditions are broken and take profit if the target is reached.
RSI (14) stands at 61.9, indicating moderate upward momentum just below the overbought zone, and moving averages maintain a bullish alignment. Trading volume is relatively subdued at 0.78 times the 20-day average, while the 7-day volatility/return rate records a strong upward momentum at +13.6%.
At the time of the prediction, the stock price was already above the existing 20-day resistance line, leading to the view that an approach after confirming the short-term support line would be valid. However, the actual result significantly exceeded the projected return of 3.5%, recording a 17.5% return and receiving an OVERHIT rating. While upward momentum was captured based on the RSI (14) of 61.9, bull-aligned moving averages, and a +13.6% volatility rate over the past 7 days, this review highlights that an even steeper additional rally unfolded than expected, driven by the convergence of an increasing trend in biotech theme news and strong buying pressure.
Since this trade confirmed the persistence of momentum in the phase above the resistance line, we will respond by flexibly allowing room for additional upside following a breakout above the short-term resistance line when an increase in news within the theme and bullish-aligned technical indicators occur simultaneously in the future.